Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer’s disease and corticobasal syndrome

This study highlights the diagnostic utility of pTau181, ApoE4 and the Aβ1-42/1-40 ratio for AD and NfL in the CBS-Aβ(-) cases and emphasizes the added value of combined biomarker models for group differentiation. Prospective studies will help validate these findings and refine clinical thresholds.

Authors

Institutions

Publication Details

Journal
European Archives of Psychiatry and Clinical Neuroscience
Published
2025-05-02
DOI
https://doi.org/10.1007/s00406-025-02013-z
Citations
7
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
8.15

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer’s disease and corticobasal syndrome

Oliver Pogarell, Maia Tatò, Robert Perneczky, Endy Weidinger et al.
7 citations
European Archives of Psychiatry and Clinical Neuroscience
Alzheimer's disease research and treatments
8.15
article

Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer’s disease and corticobasal syndrome

Oliver Pogarell, Maia Tatò, Robert Perneczky, Endy Weidinger, Boris Papazov, Sophia Stoecklein, Sayuri Hortsch, Boris‐Stephan Rauchmann, Johannes Levin, Carla Palleis, Daniel Keeser, Alexander Jethwa, Lena Burow, Matthias Brendel, Laura De Carli, Estrella Morenas‐Rodríguez, Jan Haeckert, Carolin Kurz, Carolin Koriath, Günter U. Höglinger, Isabelle Schrurs, Selim Üstün Gürsel, Julia Utecht, Margherita Carboni, Tobias Bittner
article en
7 citations

Abstract

This study highlights the diagnostic utility of pTau181, ApoE4 and the Aβ1-42/1-40 ratio for AD and NfL in the CBS-Aβ(-) cases and emphasizes the added value of combined biomarker models for group differentiation. Prospective studies will help validate these findings and refine clinical thresholds.

European Archives of Psychiatry and Clinical NeuroscienceVol. 275(8)
Roche (Switzerland) (CH), University of Augsburg (DE), German Center for Neurodegenerative Diseases (DE), Hospital de Sant Pau (ES), University Hospital Augsburg (DE), LMU Klinikum (DE), Roche Pharma AG (Germany) (DE), Munich Cluster for Systems Neurology (DE), Bezirkskrankenhaus Augsburg (DE), Imperial College London (GB), Ludwig-Maximilians-Universität München (DE), University of Sheffield (GB)
Deutsche Forschungsgemeinschaft, Helmholtz Association
Reduced inequalities
Openalex Percentile: Top 2%
Alzheimer's disease research and treatments
8.15
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.